You are correct, if JW was a well-respected, squeaky clean CEO we might be doing better right now. But I don't expect a big move until the things that are on their way ( MoA, CRP, Thyroid, Rosacea, and eventually Alzheimer studies) come out. MoA might be extremely important for medical community but my interest and I think the publics will be the Thyroid & CRP studies and their significance and they are extremely imminent. In the short term his missteps have created an amazing entry point for the investor who sees what a huge impact Anatabine will have. (I am a long) In the long run STSI could prove to be one of the best investment ever because of Anatabine's possibilities. As my last post stated, Anatabine is bigger than JW, he knows it too, I'm betting. He might be a little cocky because of it, but thats because he can say I'm the guy who found Anatabine, I can't argue with that. He has done something amazing. We wouldn't be able to diminish what Tom Brady has done if he was the cockiest ass ever because he's got 3 SBs in the bank and multiple records a.k.a. Anatabine for JW. My point is under normal circumstances I would care if the CEO acted and operated like JW but these are not normal circumstances. In the short term he has made it look like a bad investment, but in the long term Anatabine trumps it all.
AI
